Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (32)

2024

  1. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)

    Journal of the European Academy of Dermatology and Venereology

  2. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 6, pp. 547-554

  3. Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis® From the Patient's Perspective: A Systematic Review

    Dermatitis, Vol. 35, Núm. 3, pp. 216-234

  4. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study

    International Journal of Dermatology, Vol. 63, Núm. 11, pp. e289-e295

  5. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  2. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

    Journal of Investigational Allergology and Clinical Immunology

  3. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  4. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  3. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  4. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  5. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

    Life, Vol. 12, Núm. 8

  6. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series

    International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033

  7. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

    LIFE-BASEL, Vol. 12, Núm. 9

  8. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning

    International journal of environmental research and public health, Vol. 19, Núm. 17

2021

  1. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

    Anais Brasileiros de Dermatologia, Vol. 96, Núm. 6, pp. 787-790

  2. Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study

    British Journal of Dermatology

  3. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice

    Dermatologic Therapy, Vol. 34, Núm. 2